Real-world experience from the TRIO network assessing outcomes in patients with chronic hepatitis C treated with elbasvir/grazoprevirin the United States.
Phase of Trial: Phase IV
Latest Information Update: 03 Oct 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 03 Oct 2017 According to a Merck AG media release, retrospective subgroup data from this trial will be presented at The Liver Meeting 2017.
- 08 Jul 2017 New trial record